Related Experiment Video
Updated: Apr 17, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Tacrolimus decreases insulin sensitivity without reducing fasting insulin concentration: a 2-year follow-up study in
Qing-Jie Chen1, Jing Li, Shan-Ru Zuo
1Clinical Pharmacy and Pharmacology Research Institute, The Third Xiangya Hospital of Central South University , Changsha, Hunan , PR China .
Abstract:
New Onset Diabetes after Transplantation (NODAT) is defined as sustained hyperglycemia developing in patients without diabetes history before transplantation. A cohort study was performed to access the effects of tacrolimus on insulin secretion and insulin sensitivity and consequently in the development of NODAT in kidney transplant recipients. Then, we further investigated the association between NODAT and single-nucleotide polymorphisms of IRS-1 and IRS-2 in renal allograft recipients. One hundred and fifty-eight kidney transplant patients, receiving tacrolimus as the base immunosuppressant, were divided into two groups: with or without NODAT. Plasma levels of fasting insulin concentration (FINS) and C-peptide were determined by enhanced chemiluminescence immunoassay and ADVIA Centaur C peptide assay, respectively. The genotypes of Gly1057Asp in IRS-2 and Gly972Arg in IRS-1 were detected through polymerase chain reaction fragment length polymorphism in NODAT and non-NODAT patients. It was found that the concentrations of fasting plasma insulin and C-peptide in NODAT and non-NODAT patients treated with tacrolimus were higher than that in healthy volunteers (p < 0.05). Fasting plasma insulin concentration in NODAT was significantly elevated compared with than that in non-NODAT group (p < 0.05). But there are no statistical differences in fasting plasma C-peptide concentrations between NODAT and non-NODAT groups. The allele and genotype frequencies of IRS-2 Gly1057Asp and IRS-1 Gly972Arg in NODAT patients were not significantly different from non-NODAT patients (p > 0.05). In conclusion, insulin resistance is the primary cause of tacrolimus-induced NODAT. The IRS-2 Gly1057Asp and IRS-1 Gly972Arg genotypes are not related to NODAT.
Insights
New Onset Diabetes after Transplantation (NODAT) is primarily caused by insulin resistance, not specific gene variations in IRS-1 or IRS-2. Tacrolimus treatment in kidney transplant patients showed elevated insulin levels in NODAT patients, indicating resistance as the main driver.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Background:
- New Onset Diabetes after Transplantation (NODAT) is a significant complication in transplant recipients.
- Tacrolimus, a common immunosuppressant, is associated with increased NODAT risk.
- Understanding the mechanisms behind NODAT is crucial for patient management.
Purpose of the Study:
- To investigate the impact of tacrolimus on insulin secretion and sensitivity in kidney transplant recipients.
- To determine the association between NODAT and single-nucleotide polymorphisms (SNPs) in IRS-1 and IRS-2 genes.
- To identify the primary cause of tacrolimus-induced NODAT.
Main Methods:
- A cohort study involving 158 kidney transplant patients treated with tacrolimus.
- Division of patients into NODAT and non-NODAT groups.
- Measurement of plasma fasting insulin and C-peptide levels.
- Genotyping of IRS-2 Gly1057Asp and IRS-1 Gly972Arg polymorphisms using PCR fragment length polymorphism.
Main Results:
- Patients with NODAT and non-NODAT groups treated with tacrolimus exhibited higher fasting insulin and C-peptide levels than healthy volunteers.
- Fasting plasma insulin levels were significantly higher in the NODAT group compared to the non-NODAT group.
- No significant differences were observed in C-peptide levels or in the allele/genotype frequencies of IRS-2 Gly1057Asp and IRS-1 Gly972Arg between NODAT and non-NODAT patients.
Conclusions:
- Insulin resistance is the principal factor contributing to tacrolimus-induced NODAT.
- The studied genetic variations in IRS-2 and IRS-1 do not appear to be associated with the development of NODAT in this cohort.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Kidney Transplant III: Nursing Management

